Manufacturing, Cell Therapies

Catalent Acquires Bone Therapeutics’ Cell Manufacturing Facility

October 29, 2020

Catalent has signed an agreement with Bone Therapeutics for the acquisition of Skeletal Cell Therapy Support SA (SCTS).

Navigating Cell Therapy Manufacturing Amid Pandemic Woes

October 21, 2020

Automation, digitalization, and supply-chain strategies help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.

Orgenesis Completes Koligo Acquisition and Gains Icellator Technology in Related Transaction

October 20, 2020

Orgenesis has completed its previously announced acquisition of Koligo Therapeutics with the additional acquisition of Tissue Genesis’ cell isolation technology, Icellator.

Thermo Fisher Scientific Launches Closed System for Cell Therapy Manufacturing

October 20, 2020

The company’s new closed cell therapy processing system enables scalable, cost-effective development and manufacturing of cell therapies.

MilliporeSigma Launches Lentiviral Production Platform for Cell and Gene Therapies

October 16, 2020

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

Akron Bio Will Install a Cytiva FlexFactory to Manufacture Plasmid DNA

October 15, 2020

Cytiva will provide the first FlexFactory to be used in the manufacture of pDNA to Akron Bio.

Cellular and Gene Therapies Face a Manufacturing Capacity Crunch

October 02, 2020

Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.

Fujifilm Irvine Scientific Becomes Worldwide Distributor of Cellnest

September 30, 2020

Cellnest will join Fujifilm Irvine Scientific’s PRIME-XV portfolio which consists of xeno-free and chemically defined media for stem cell culture.

Catalent and T-knife Enter into a Technology Transfer and Manufacturing Agreement

September 21, 2020

Catalent will use T-knife´s TCR platform for a T-cell receptor-based cell therapy at its Gosselies, Belgium, site in order to manufacture clinical batches for European trials in 2021.

Takeda Opens New R&D Cell Therapy Manufacturing Facility

September 17, 2020

The new facility will produce cell therapies for clinical evaluation from discovery through to Phase 2b trials while expanding Takeda’s abilities to develop next-generation cell therapies.